+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ophthalmic Drugs Market by Product Type, Drug Class, Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast to 2030- Product Image
Ophthalmic Drugs Market by Product Type, Drug Class, Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast to 2030- Product Image
Sale

Ophthalmic Drugs Market by Product Type, Drug Class, Dosage Form, Route of Administration, Therapeutic Area, Patient Demographics, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968753
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ophthalmic Drugs Market grew from USD 41.55 billion in 2024 to USD 44.45 billion in 2025. It is expected to continue growing at a CAGR of 7.30%, reaching USD 63.41 billion by 2030.

Unveiling the Dynamics Shaping the Ophthalmic Drugs Market

The ophthalmic drugs market is entering a phase defined by rapid innovation, escalating patient demand, and evolving regulatory landscapes. Advances in molecular therapies and digital diagnostics are converging to transform treatment paradigms for conditions ranging from dry eye syndrome to complex retinal disorders. Concurrently, demographic trends such as an aging global population and increased screen time elevate the prevalence of ocular diseases, intensifying pressure on healthcare systems to adopt more effective and accessible therapies.

In this report, we lay the groundwork by highlighting the major drivers that are reshaping the competitive environment. We examine how shifts in payer frameworks, the rise of telemedicine, and the integration of artificial intelligence in diagnostic workflows are forging new pathways for drug development and delivery. By framing the current state of the market, this introduction sets the stage for deeper analyses of regulatory changes, segment performance, regional dynamics, and strategic imperatives that can guide stakeholders through a rapidly shifting landscape.

Emerging Trends Redefining Ophthalmic Therapeutics

Over the past few years, the ophthalmic sector has witnessed transformative shifts that are redefining patient care and commercial strategies. Precision therapies, including gene editing and biologics, are moving from experimental stages into clinical practice, offering new hope for inherited retinal diseases and refractory glaucoma. Simultaneously, digital therapeutics and telehealth platforms are expanding access to screening tools and monitoring, enabling earlier intervention and improving outcomes.

Moreover, regulatory bodies are increasingly harmonizing requirements across regions, accelerating the approval of combination therapies and innovative delivery systems. Strategic partnerships between pharmaceutical companies, biotech firms, and tech startups are now common, fostering cross-disciplinary collaboration. Combined with heightened focus on real-world evidence and patient-reported outcomes, these developments are establishing a more agile environment for ophthalmic drug commercialization and long-term patient management.

Evaluating the 2025 US Tariff Effects on Ophthalmic Supply Chains

The introduction of new tariff measures in the United States during 2025 is set to have a profound cumulative impact on the ophthalmic drugs value chain. Increased duties on active pharmaceutical ingredients and finished formulations sourced from key international suppliers will elevate production costs, prompting manufacturers to reassess sourcing strategies. Many companies are now evaluating near-shoring and domestic manufacturing investments to mitigate the financial burden of import levies.

In parallel, these tariff shifts are compelling stakeholders to reexamine pricing models and contract negotiations with payers. As cost pressures mount, pharmaceutical entities may accelerate partnerships with contract development and manufacturing organizations located within preferential trade zones. Despite these adjustments, the overall market resilience remains strong, driven by the imperative to address a growing patient base. By analyzing supply-chain realignment, cost-pass-through scenarios, and strategic procurement, this section elucidates how organizations can adapt to maintain profitability and continuity of care.

Deep Dive into Ophthalmic Market Segmentation Layers

A nuanced understanding of market segmentation reveals where growth and investment opportunities lie within the ophthalmic drugs sector. Insight into product classification highlights the balance between Over-The-Counter treatments and Prescription drugs, each catering to distinct patient needs and reimbursement pathways. Delving deeper, the spectrum of drug classes spans Anti-Allergics, Anti-Glaucoma Agents, Anti-Inflammatories differentiated into Non-Steroidal and Steroidal categories, Antibiotics subdivided into Aminoglycosides, Fluoroquinolones, Macrolides, and Tetracyclines, as well as Antifungal, Antiviral, and Combination drugs.

Variations in delivery format-from eye drops and gels to ointments and oral tablets or capsules-play a critical role in driving adherence and convenience. Route of administration considerations, whether Injectable, Oral, or Topical, align with clinical severity and treatment setting. Therapeutic focus spans Cataracts, Conjunctivitis with allergic, bacterial, and viral subtypes, Dry Eye Syndrome, Glaucoma, Ocular Infections, and Retinal Disorders. Patient demographics further segment the market across Adult, Geriatric, and Pediatric cohorts, while end users range from Hospitals and Online Pharmacies to Ophthalmic Clinics and Retail Pharmacies & Drug Stores. By mapping performance across these layers, stakeholders can prioritize high-growth niches and tailor development strategies for maximum impact.

Navigating Regional Variations in Ophthalmic Drug Adoption

Regional dynamics in the ophthalmic drugs market underscore significant variances in regulatory frameworks, patient access, and competitive intensity. In the Americas, the United States dominates through substantial R&D investment and strong intellectual property protections, while Latin American markets are characterized by growing private-sector participation and gradual reimbursement expansion.

Across Europe, the Middle East & Africa, diverse regulatory pathways and reimbursement models present both challenges and opportunities. High-income European nations exhibit mature tender systems and centralized approval processes, whereas Middle Eastern and African markets often rely on parallel importation and public-private partnerships to improve drug availability.

Within Asia-Pacific, markets such as Japan and Australia demonstrate rapid uptake of innovative therapies, supported by favorable regulatory initiatives. Emerging markets in Southeast Asia and India are experiencing increased penetration of generic ophthalmic drugs, driven by cost-sensitive healthcare infrastructures and expanding insurance coverage. Understanding these regional distinctions enables companies to align launch strategies with local market drivers and patient needs.

Strategic Moves Shaping Competitive Leadership

Key players in the ophthalmic drugs sector are pursuing diverse strategies to secure market leadership. Legacy pharmaceutical companies with extensive portfolios in eye care are reinforcing their pipelines through acquisitions of biotech innovators and licensing agreements for next-generation molecules. At the same time, specialty biotech firms are gaining traction by advancing cutting-edge gene therapies and sustained-release drug delivery platforms.

Competitive positioning is also influenced by strategic collaborations between research institutions and commercial partners, accelerating time to market for novel treatments. Additionally, investments in manufacturing scale-up for high-value generics are enabling mid-tier companies to capture share in cost-sensitive segments. By monitoring alliances, patent expirations, and portfolio diversification across major and emerging players, stakeholders can anticipate shifts in market share and identify potential targets for partnership or acquisition.

Proactive Strategies to Secure Market Leadership

Industry leaders must adopt proactive measures to thrive amid evolving market dynamics. First, prioritizing investment in gene and cell therapies will position organizations at the forefront of personalized ocular care. Simultaneously, diversifying supply chains through regional manufacturing hubs can alleviate tariff-related cost pressures and ensure consistent product availability.

Engaging payers with robust pharmacoeconomic data will support favorable reimbursement outcomes, especially for high-cost specialty treatments. Embracing digital health solutions, from remote monitoring to AI-driven diagnostics, can enhance patient adherence and capture real-world evidence that feeds back into clinical development. Finally, forming targeted alliances-whether with academic centers, contract manufacturers, or technology providers-will accelerate innovation pipelines and amplify go-to-market capabilities in both established and emerging markets.

Rigorous Hybrid Research Framework Ensuring Data Integrity

This research is built upon a comprehensive methodology that integrates both secondary and primary research. The secondary phase involved rigorous analysis of peer-reviewed journals, regulatory databases, and industry publications to establish a robust baseline of market dynamics, drug approvals, and technological trends. Complementing this, primary interviews were conducted with senior executives, clinical experts, and key opinion leaders across major geographic regions to validate assumptions and uncover emerging viewpoints.

Data triangulation ensured consistency and accuracy, with quantitative insights cross-referenced against multiple sources. Segmentation matrices were constructed to map performance across product types, therapeutic classes, dosage forms, administration routes, and end-user channels. Regional analyses synthesized local regulatory and reimbursement frameworks. Finally, a peer review process by internal analysts and external advisors was undertaken to ensure methodological rigor and the highest standard of quality in the presentation of findings.

Concluding Insights Illuminating the Path Forward

In summary, the ophthalmic drugs market stands at the cusp of a transformative era driven by advanced therapeutics, digital integration, and strategic supply chain realignment. While new tariff measures in the United States pose challenges, they also catalyze innovation in manufacturing and sourcing. Detailed segmentation analysis reveals high-growth opportunities across therapeutic classes, dosage formats, patient demographics, and distribution channels.

Regional insights emphasize the need for tailored approaches in the Americas, Europe, Middle East & Africa, and Asia-Pacific, each with unique regulatory and market access considerations. Competitive intelligence underscores the importance of alliances and pipeline diversification. By adopting the actionable recommendations outlined, industry participants can navigate uncertainties and capitalize on the evolving landscape to deliver improved patient outcomes and sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Over-The-Counter Drugs
    • Prescription Drugs
  • Drug Class
    • Anti-Allergics
    • Anti-Glaucoma Agents
    • Anti-Inflammatories
      • Non-Steroidal Anti-Inflammatories
      • Steroidal Anti-Inflammatories
    • Antibiotics
      • Aminoglycosides
      • Fluoroquinolones
      • Macrolides
      • Tetracyclines
    • Antifungal
    • Antiviral
    • Combination Drugs
  • Dosage Form
    • Eye Drops
    • Gels
    • Ointments
    • Tablets & Capsules
  • Route of Administration
    • Injectable
    • Oral
    • Topical
  • Therapeutic Area
    • Cataracts
    • Conjunctivitis
      • Allergic Conjunctivitis
      • Bacterial Conjunctivitis
      • Viral Conjunctivitis
    • Dry Eye Syndrome
    • Glaucoma
    • Ocular Infections
    • Retinal Disorders
  • Patient Demographics
    • Adult
    • Geriatric
    • Pediatric
  • End User
    • Hospitals
    • Online Pharmacies
    • Ophthalmic Clinics
    • Retail Pharmacies & Drug Stores
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • Alcon Vision LLC
  • Allergan PLC by AbbVie Inc.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Johnson & Johnson Service, Inc.
  • Kodiak Sciences Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Merck & Co.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ophthalmic Drugs Market, by Product Type
8.1. Introduction
8.2. Over-The-Counter Drugs
8.3. Prescription Drugs
9. Ophthalmic Drugs Market, by Drug Class
9.1. Introduction
9.2. Anti-Allergics
9.3. Anti-Glaucoma Agents
9.4. Anti-Inflammatories
9.4.1. Non-Steroidal Anti-Inflammatories
9.4.2. Steroidal Anti-Inflammatories
9.5. Antibiotics
9.5.1. Aminoglycosides
9.5.2. Fluoroquinolones
9.5.3. Macrolides
9.5.4. Tetracyclines
9.6. Antifungal
9.7. Antiviral
9.8. Combination Drugs
10. Ophthalmic Drugs Market, by Dosage Form
10.1. Introduction
10.2. Eye Drops
10.3. Gels
10.4. Ointments
10.5. Tablets & Capsules
11. Ophthalmic Drugs Market, by Route of Administration
11.1. Introduction
11.2. Injectable
11.3. Oral
11.4. Topical
12. Ophthalmic Drugs Market, by Therapeutic Area
12.1. Introduction
12.2. Cataracts
12.3. Conjunctivitis
12.3.1. Allergic Conjunctivitis
12.3.2. Bacterial Conjunctivitis
12.3.3. Viral Conjunctivitis
12.4. Dry Eye Syndrome
12.5. Glaucoma
12.6. Ocular Infections
12.7. Retinal Disorders
13. Ophthalmic Drugs Market, by Patient Demographics
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Ophthalmic Drugs Market, by End User
14.1. Introduction
14.2. Hospitals
14.3. Online Pharmacies
14.4. Ophthalmic Clinics
14.5. Retail Pharmacies & Drug Stores
15. Americas Ophthalmic Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Ophthalmic Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Ophthalmic Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Alcon Vision LLC
18.3.3. Allergan PLC by AbbVie Inc.
18.3.4. Apotex Inc.
18.3.5. Bausch Health Companies Inc.
18.3.6. Bayer AG
18.3.7. Carl Zeiss AG
18.3.8. EyePoint Pharmaceuticals, Inc.
18.3.9. Genentech, Inc.
18.3.10. Johnson & Johnson Service, Inc.
18.3.11. Kodiak Sciences Inc.
18.3.12. Lotus Pharmaceutical Co., Ltd.
18.3.13. Lupin Limited
18.3.14. Merck & Co.
18.3.15. Nicox SA
18.3.16. Novartis AG
18.3.17. Ocular Therapeutix, Inc.
18.3.18. OCuSOFT Inc.
18.3.19. Pfizer Inc.
18.3.20. Regeneron Pharmaceuticals, Inc.
18.3.21. Santen Pharmaceutical Co., Ltd.
18.3.22. Senju Pharmaceutical Co.,Ltd.
18.3.23. Somerset Pharma, LLC.
18.3.24. Sun Pharmaceutical Industries, Inc.
18.3.25. Takeda Pharmaceutical Company Limited
18.3.26. Viatris Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. OPHTHALMIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. OPHTHALMIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY STEROIDAL ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CATARACTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY BACTERIAL CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY VIRAL CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 79. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 80. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 81. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 84. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 89. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 93. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 140. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 144. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 150. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 152. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 154. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 170. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 171. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 172. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 174. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 175. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 180. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 184. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 220. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 221. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 224. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 240. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 241. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 242. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 244. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 245. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 250. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 251. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 252. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 254. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 255. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 256. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 280. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 281. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 285. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 290. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 291. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 294. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 295. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 296. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 310. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 311. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 312. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 314. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 315. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 316. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 320. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 321. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 322. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 324. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 325. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 326. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 331. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 332. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 334. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 335. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 336. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2030 (USD MILLION)
TABLE 340. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 341. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 342. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 343. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 344. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2018-2030 (USD MILLION)
TABLE 345. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 346. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018

Companies Mentioned

The companies profiled in this Ophthalmic Drugs market report include:
  • Abbott Laboratories
  • Alcon Vision LLC
  • Allergan PLC by AbbVie Inc.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • EyePoint Pharmaceuticals, Inc.
  • Genentech, Inc.
  • Johnson & Johnson Service, Inc.
  • Kodiak Sciences Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Merck & Co.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 44.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 63.41 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Steroidal Drugs, Anti-VEGF Agents), Disease, Dosage Form, Route of Administration, Product Type, Drug Type, and Region with Growth Forecasts, 2025-2030 - Product Image

Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Steroidal Drugs, Anti-VEGF Agents), Disease, Dosage Form, Route of Administration, Product Type, Drug Type, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Ophthalmic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Ophthalmic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast to 2030 - Product Image

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Ophthalmic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Eye Drops, Contact Lenses), By Delivery Route, By Production Technology, By Material, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Ophthalmic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Eye Drops, Contact Lenses), By Delivery Route, By Production Technology, By Material, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 190 Pages
  • Global
From
Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2025-2033 - Product Image

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.